Volume 5 ; Issue 1 ; in Month : Jan-June (2022) Article No : 140
Jahangir MA, Kumar N, Shahab MS

Abstract

Cancer stands as one of the leading causes of death globally. Its socio-economic burden is increasing day by day. There is no defined treatment strategy for cancer. In most of the cases a combinatorial therapy approach is utilised which includes surgery, chemotherapy, immune therapy, radiation therapy etc. Immune checkpoints are a revolutionary discovery in cancer immunotherapy. Dostarlimab is an anti-programmed cell death protein-1 (PD-1) immunoglobulin G4 (IgG4) humanised monoclonal antibody (mAb), produced by recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells. PD-1 is an immune checkpoint receptor expressed by T-cells which has shown to suppress cancer-specific immune responses. In this article we provide the recent known information regarding dostarlimab along with currently undergoing 44 clinical trials globally with its title, conditions, interventions, and outcome measures.

Full Text Attachment

Views : 362      Downloads : 4

RSS